Compare EPM & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EPM | ADCT |
|---|---|---|
| Founded | 2003 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.7M | 136.1M |
| IPO Year | 1996 | 2019 |
| Metric | EPM | ADCT |
|---|---|---|
| Price | $3.49 | $1.43 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $4.88 | $3.33 |
| AVG Volume (30 Days) | 362.1K | ★ 1.2M |
| Earning Date | 11-10-2026 | 11-09-2026 |
| Dividend Yield | ★ 13.83% | N/A |
| EPS Growth | N/A | ★ 30.86 |
| EPS | ★ N/A | N/A |
| Revenue | $43,229,621.00 | ★ $81,357,000.00 |
| Revenue This Year | $6.78 | N/A |
| Revenue Next Year | N/A | $25.89 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $3.19 | $0.78 |
| 52 Week High | $4.99 | $4.98 |
| Indicator | EPM | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 40.34 | 46.57 |
| Support Level | $3.40 | $1.39 |
| Resistance Level | $3.85 | $1.45 |
| Average True Range (ATR) | 0.15 | 0.17 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 33.41 | 5.43 |
Evolution Petroleum Corp is an independent energy company focused on owning and investing in onshore oil and natural gas properties across the United States. Its portfolio includes non-operated interests in various production fields such as CO2 enhanced oil recovery in Louisiana, secondary recovery production in Wyoming, and shale gas reservoirs in Texas and North Dakota. The company generates revenue from the production and sale of oil and natural gas, leveraging specialized technologies to extend reservoir life and enhance recoveries.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).